CHICAGO — A real-world study of the ocular side effects of the gynecological cancer treatment mirvetuximab (Elahere) has ...

These novel candidates are typically intended to optimize one or more of the core ADC design features—the target ... 7 (PTK7), are also in phase 1/2 trials. • Genmab agreed to pay $1.8 billion ...

There’s a new Muse in town. Sanofi, Formation Bio and OpenAI have joined forces to build an AI-powered tool designed to ...

Streamlining processes like trial site selection and FDA documentation can make a meaningful difference in development ...

Improving Protocol Design with RWD Protocol design is the backbone of any clinical trial, outlining study objectives, patient selection criteria, endpoints, and procedures. One of the most ...

ImmunoGen, Inc. has announced that its platinum-resistant ovarian cancer drug ELAHERE (mirvetuximab soravtansine-gynx) has been granted FDA accelerated approval. This first FDA antibody-drug ...

As the target FolRα has been validated by approval and successful launch of AbbVie's (ABBV) Elahere (acquired ImmunoGen ... much faster in terms of getting trials up and running & enrolling ...

The time is now to align on a shared plan of action as a country to achieve diversity, equity, inclusion, and access in US ...

Mirvetuximab soravtansine demonstrated efficacy in heavily pretreated patients with FRα+, platinum-sensitive ovarian cancer, achieving a 51.9% objective response rate in the PICCOLO trial.

Additionally, positive findings from trials like ADRIATIC (NCT03703297) and IMforte (NCT05091567) are further shaping ...